Valuation: Chugai Pharmaceutical Co., Ltd.

Capitalization 13,000B 81.86B 70.39B 64.44B 60.88B 113B 7,906B 114B 764B 299B 3,732B 307B 301B P/E ratio 2026 *
25.5x
P/E ratio 2027 * 22.1x
Enterprise value 12,030B 75.75B 65.14B 59.63B 56.34B 104B 7,316B 106B 707B 277B 3,454B 284B 278B EV / Sales 2026 *
8.7x
EV / Sales 2027 * 7.74x
Free-Float
38.12%
Yield 2026 *
1.73%
Yield 2027 * 1.95%
1 day-0.20%
1 week-2.63%
Current month-2.87%
1 month-9.33%
3 months-21.95%
6 months-5.80%
Current year-4.37%
1 week 7,787
Extreme 7787
8,151
1 month 7,402
Extreme 7402
9,013
Current year 7,402
Extreme 7402
10,700
1 year 5,942
Extreme 5942
10,700
3 years 3,601
Extreme 3601
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2021
Director of Finance/CFO - 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 01/03/1993
Director/Board Member 81 01/03/2015
Director/Board Member 77 01/03/2017
Change 5d. change 1-year change 3-years change Capi.($)
-0.13%-2.63%+6.96%+113.00% 82.07B
-0.25%+0.31%+36.39%+130.32% 911B
-0.30%-0.48%+49.24%+44.31% 554B
-0.68%+1.82%+14.85%+46.30% 378B
-0.42%+2.53%+24.56%+13.82% 333B
+0.50%+1.34%+33.90%+16.15% 288B
-0.42%+1.49%+27.07%+30.97% 287B
-1.09%-0.40%+44.93%-2.16% 282B
+0.31%-3.61%-36.78%-49.84% 198B
+0.25%-1.45%+20.57%+48.41% 179B
Average -0.27%+1.03%+22.17%+39.13% 349.15B
Weighted average by Cap. -0.39%+1.19%+29.04%+53.37%

Financials

2026 *2027 *
Net sales 1,382B 8.7B 7.48B 6.85B 6.47B 11.96B 841B 12.15B 81.22B 31.78B 397B 32.66B 31.97B 1,521B 9.58B 8.24B 7.54B 7.12B 13.17B 925B 13.38B 89.4B 34.98B 437B 35.95B 35.19B
Net income 511B 3.21B 2.76B 2.53B 2.39B 4.42B 310B 4.49B 30B 11.74B 147B 12.06B 11.81B 589B 3.71B 3.19B 2.92B 2.76B 5.1B 358B 5.18B 34.6B 13.54B 169B 13.91B 13.62B
Net Debt -970B -6.11B -5.25B -4.81B -4.54B -8.4B -590B -8.53B -57.02B -22.31B -279B -22.93B -22.44B -1,226B -7.72B -6.64B -6.08B -5.74B -10.61B -746B -10.78B -72.06B -28.2B -352B -28.98B -28.36B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
21/05/26 7,889.00 ¥ -0.13% 1,019,000
20/05/26 7,899.00 ¥ -0.47% 2,507,400
19/05/26 7,936.00 ¥ +0.65% 2,367,900
18/05/26 7,885.00 ¥ -0.67% 1,512,400
15/05/26 7,938.00 ¥ -1.95% 2,260,800
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,899.00JPY
Average target price
10,096.67JPY
Spread / Average Target
+27.82%

Quarterly revenue - Rate of surprise